WO1995028479A1 - Verfahren zur herstellung von dendritischen zellen, so erhaltene zellen und behälter zur durchführung dieses verfahrens - Google Patents
Verfahren zur herstellung von dendritischen zellen, so erhaltene zellen und behälter zur durchführung dieses verfahrens Download PDFInfo
- Publication number
- WO1995028479A1 WO1995028479A1 PCT/DE1995/000512 DE9500512W WO9528479A1 WO 1995028479 A1 WO1995028479 A1 WO 1995028479A1 DE 9500512 W DE9500512 W DE 9500512W WO 9528479 A1 WO9528479 A1 WO 9528479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- interleukin
- csf
- cell growth
- peripheral blood
- Prior art date
Links
- 210000004027 cell Anatomy 0.000 title claims abstract description 142
- 210000004443 dendritic cell Anatomy 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 39
- 230000008569 process Effects 0.000 title abstract description 8
- 239000000427 antigen Substances 0.000 claims abstract description 29
- 102000036639 antigens Human genes 0.000 claims abstract description 29
- 108091007433 antigens Proteins 0.000 claims abstract description 29
- 239000003102 growth factor Substances 0.000 claims abstract description 26
- 102000004127 Cytokines Human genes 0.000 claims abstract description 22
- 108090000695 Cytokines Proteins 0.000 claims abstract description 22
- 210000004369 blood Anatomy 0.000 claims abstract description 19
- 239000008280 blood Substances 0.000 claims abstract description 19
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 12
- 239000002243 precursor Substances 0.000 claims abstract description 11
- 230000003394 haemopoietic effect Effects 0.000 claims abstract description 6
- 210000004976 peripheral blood cell Anatomy 0.000 claims abstract 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 39
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 39
- 102000003951 Erythropoietin Human genes 0.000 claims description 31
- 108090000394 Erythropoietin Proteins 0.000 claims description 31
- 108010002386 Interleukin-3 Proteins 0.000 claims description 31
- 102000000646 Interleukin-3 Human genes 0.000 claims description 31
- 102000004889 Interleukin-6 Human genes 0.000 claims description 31
- 108090001005 Interleukin-6 Proteins 0.000 claims description 31
- 229940105423 erythropoietin Drugs 0.000 claims description 31
- 229940076264 interleukin-3 Drugs 0.000 claims description 31
- 229940100601 interleukin-6 Drugs 0.000 claims description 31
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 31
- 102000004388 Interleukin-4 Human genes 0.000 claims description 27
- 108090000978 Interleukin-4 Proteins 0.000 claims description 27
- 229940028885 interleukin-4 Drugs 0.000 claims description 24
- 210000005259 peripheral blood Anatomy 0.000 claims description 20
- 239000011886 peripheral blood Substances 0.000 claims description 20
- 210000000130 stem cell Anatomy 0.000 claims description 20
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 19
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 19
- 102000000589 Interleukin-1 Human genes 0.000 claims description 18
- 108010002352 Interleukin-1 Proteins 0.000 claims description 18
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 238000002512 chemotherapy Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 230000004069 differentiation Effects 0.000 claims description 8
- 229920001917 Ficoll Polymers 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 claims description 2
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 claims description 2
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 15
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 15
- 230000010261 cell growth Effects 0.000 claims 4
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 description 13
- 210000005087 mononuclear cell Anatomy 0.000 description 12
- 210000001821 langerhans cell Anatomy 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
- 229960000814 tetanus toxoid Drugs 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 7
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 108090001008 Avidin Proteins 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- -1 SCF Proteins 0.000 description 5
- 239000012894 fetal calf serum Substances 0.000 description 5
- 210000001616 monocyte Anatomy 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002617 apheresis Methods 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000003021 clonogenic effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 210000002664 langerhans' cell Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 1
- 101000887490 Homo sapiens Guanine nucleotide-binding protein G(z) subunit alpha Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011254 conventional chemotherapy Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 102000052301 human GNAZ Human genes 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003211 trypan blue cell staining Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/46482—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/25—Tumour necrosing factors [TNF]
Definitions
- the present invention relates to the provision of dendritic cells which can not only be used in basic research but can also be used advantageously in a therapeutic respect.
- a method for producing human dendritic cells is known from EPA 92.400879.0. This procedure treats CD 34 + cells with tumor necrosis factor- ⁇ (TNF- ⁇ ) and either interleukin-3 or GM-CSF. However, it has been found that the desired cells cannot be obtained in the required yield and purity in this process.
- TNF- ⁇ tumor necrosis factor- ⁇
- GM-CSF interleukin-3
- Dendritic cells are the most potent antigen-presenting cells in the organism. They are derived from bone marrow progenitor cells and circulate less Number in the peripheral blood and show up as so-called Langerhans cells or terminally differentiated cells (dendritic cells) in the epidermis of the skin, the gastrointestinal mucosa, visceral pleura or epitelia of the urogenital tract.
- these cells migrate from the skin into the paracortex of draining lymph nodes, where, as terminally differentiated cells, they trigger a specific T cell response.
- the function as antigen-presenting cells can be demonstrated in vitro in the autologous and allogeneic "mixed lymphocyte reaction" and in test systems in which soluble antigens are added.
- the dendritic cells can be differentiated from monocytes / macrophages, which are also antigen-presenting cells but express other surface markers.
- a distinctive marker is in particular the CD 14 antigen, which is not found in dendritic cells, whereas monocytes or macrophages have this antigen.
- the dendritic cells do not have this property.
- the surface antigens of the circulating dendritic cells can be defined as follows: CDla + , CDlc + , CD 13 + , CD 33 + , CD 14 " , CD 16 ⁇ , CD 3 " , CD 19 " , MHC II + .
- MHC-II molecules likewise there is expression of CD 25, B 7, CD 40 and ICAM 1.
- the dendritic cells are antigen-presenting cells that can induce the activation of T cells with high efficiency. They are highly specialized and optimally equipped for their task, because dendritic cells express in large quantities Molecules that are necessary for the presentation of antigen (MHCI and MHCII). In addition, these cells express the constitutive costimulatory molecules CD80 and CD86 on their surface. These molecules are essential for the activation of the T cells. There are also important adhesion molecules on the surface of the dendritic cells, which guarantee intimate contact with the target cell.
- the cells of the Langerhans * see type (short: LC) are distributed over the body in non-lymphatic organs. Your task is to absorb and process antigen. There are no specific markers for these cells, but they express the following markers: CD la, CD 11b, CD 33, HLA-DR and CD 80. A more specific detection is possible by electron microscopy. The so-called Birbeck granules, which only have Langerhans's cells, can be detected by electron microscopy.
- Langerhans's cells migrate from the periphery of the body to the lymphatic organs via the lymphatic system. In this way, they differentiate into mature immunostimulatory dendritic cells that no longer take up antigen, but instead induce strong T cell responses.
- DC dendritic cells
- the dendritic cells can be used, for example, in the reinforcement of anti-infectious therapy.
- the antigen-presenting dendritic cells are of particular importance in viral and bacterial infections and an addition of these cells to the corresponding ones Infections can have beneficial effects on the patient, particularly in severe cases.
- Another area of application would be vaccination because it strengthens the body's immune response.
- the cells that can be produced by the method according to the invention are of particular importance because of their strong antigen presentation.
- the dendritic cells obtainable according to the invention can be loaded with specific antigens for various vaccination therapies in order to induce a specific T cell response in this way.
- the use of the dendritic cells obtainable according to the invention is of great importance in the immunotherapy of malignant or also infectious diseases.
- the dendritic cells that can be produced according to the invention can be obtained individually from each patient and, for example, can be loaded with specific tumor antigens in adoptive tumor immunotherapy, can be retransfused to the patient, and thus a specific immune response against the tumor can be induced.
- the dendritic cells obtainable according to the invention can be used to intensify a vaccination reaction in immunosuppressed patients, for example in the case of hepatitis vaccination and, if appropriate, in the case of vaccination against HIV viruses.
- the dendritic cells obtainable according to the invention can also be used advantageously in other vaccinations.
- dendritic cells can be used in particular in the therapy of minimally residual diseases.
- tumor-specific antigens are presented by the dendritic cells, which then cause a T-cell-specific (cytotoxic) reaction.
- the method according to the invention for the ex vivo expansion of dendritic cells can be carried out as follows: heparinized blood samples are obtained from the patients. In the method according to the invention it is possible to start from cells which have been isolated from blood. This represents a considerable advantage over the method known from EPA 92.400879.0, in which the cells have to come from the bone marrow or the blood of the umbilical cord.
- Mononuclear cells (MNZ) can preferably be isolated from the apheresis product by suitable separation techniques, in particular by density gradient centrifugation via Ficoll (Pharmacia, Germany).
- the CD 34 + cells can be obtained from leukapheresate, in which the mononuclear cells are already enriched.
- the mononuclear cells can be enriched by density centrifugation both when the CD 34 + cells are obtained directly from the blood and when the CD 34 + cells are obtained from leukapheresate. Density centrifugation is preferred, but not essential.
- CD 34 + cells were obtained directly from the blood (heparinized blood samples), lysis of the erythrocytes could be sufficient and the next purification step could be followed by an affinity column or another enrichment step. If the CD 34 + cells are obtained directly from the leukapheresate, the cells can only be placed on an affinity column (for example CellPro) after a washing process, even without Ficoll separation. Enrichment by means of Ficoll gradients can be dispensed with in particular if relatively large quantities of CD 34 + cells are already present, as can be the case, for example, with high-dose chemotherapy.
- an affinity column for example CellPro
- the method for providing dendritic cells can comprise the following steps:
- the erythrocytes can be lysed
- a CD 34 isolation process can be carried out, which in a particularly preferred embodiment is an efficiency chromatography step;
- the Langerhans cells / dendritic cells obtained in this way can be further treated depending on the intended use and then returned to the patient. Especially if If larger amounts of Langerhans cells / dendritic cells are required, leukapheresis would be helpful for stem cell enrichment.
- the mononuclear cells are further treated to enrich those cells that have the CD 34 surface antigen.
- Berenson et al. described the CD 34 antigen.
- These cells can be enriched by incubating the cells with a monoclonal antibody which is specific for the CD 34 antigen, the antibody preferably being biotinylated.
- monoclonal antibodies can be purchased commercially, for example from Dianova, Coulter, CellPro or Becton Dickinson.
- the cells treated with the monoclonal antibody are loaded on immunoaffinity columns, preferably avidin immunoaffinity columns, the avidin binding the monoclonal antibodies and consequently also the CD 34 + cells bound to them.
- the absorbed cells with the CD 34 surface antigen are removed from the immunoaffinity column and placed in a suitable medium.
- the monoclonal antibodies specific for the CD 34 antigen could also be bound directly to a solid phase (for example small beads, etc.) in order to fix the CD 34 + cells and remove them from the mixture.
- a solid phase for example small beads, etc.
- CD 34 + cells it is also possible to enrich the CD 34 + cells using a fluorescence activated cell sorter, which is commercially available, for example from Becton Dickinson.
- a fluorescence activated cell sorter which is commercially available, for example from Becton Dickinson.
- mobilized peripheral blood precursor cells are reacted with an anti-CD 34 antibody that has a fluorochrome label.
- the fluorescence-activated cell sorter it is possible to separate the cells in order to obtain the CD 34 + cells. On in this way, highly purified cells can be obtained.
- Another possibility would be to separate the CD 34 + cells in that magnetic beads are used (beads) which are commercially available from Dynal, Baxter, Milteny and other companies.
- the enriched CD 34 + cells were then cultivated in a suitable culture medium.
- a suitable culture medium is, for example, supplemented RPMI 1640 medium which contains 10% fetal calf serum.
- the culture medium can also contain heparinized autologous plasma, preferably in a concentration of about 1%.
- the RPMI 1640 medium which is supplemented with 200 mM L-glutamine, 50 ⁇ M ⁇ -mercaptoethanol, 100 mM sodium pyruvate, 50 ⁇ g / ml streptomycin, 50 U / ml penicillin, MEM vitamins and 10 is preferably used as the culture medium % fetal calf serum.
- the cells were grown in the presence of a combination of different growth factors.
- the following growth factors were used:
- Interleukin-1 (IL-1) described by Gery I. et al., Method Enzymol. 116, 456-467 (1985); Lachmann et al., Methods Enzymol. 116, 467-497 (1985); March et al., Nature 315: 641 (1985);
- Interleukin-3 described in EPA 138 133, Ihle et al., Methods Enzymol. 116: 540-552 (1985); Otsuka et al., J. Immunol. 140: 2288-2295 (1988);
- Interleukin-4 available from Genzyme Corp .
- Interleukin-6 described in Brakenhoff et al., J. Immunol. 139: 4116-4121 (1987), Brakenhoff et al., J. Immunol. 143: 1175-1182 (1989); Granulocyte-macrophage colony stimulating factor (GM-CSF) available from Genzyme Corp .;
- EPO Erythropoietin
- SCF Stem cell factor
- IFN-Y Interferon-Y
- EP 77 670 Gray et al., Nature 295, 503-508 (1982); Devos et al., Nucl. Acids Res. 10: 2487-2501 (1982); Yip et al., PNAS 79, 1820-1824 (1982) and Braude, Methods Enzymol. 119, 193-199 (1986).
- the cells are cultivated in the presence of the growth factors IL-1, IL-3, IL-6, EPO and SCF. It is essential that the cells are cultivated in the presence of a stem cell factor, and the medium must also contain further cytokines or growth factors.
- the cells are expanded in the presence of a combination of SCF, GM-CSF and TNF- ⁇ .
- additional IL-4 Interleukin-4
- IL-4 Interleukin-4
- differentiation into dendritic cells is carried out by using the cytokines IL-1ß, IL-3, IL-6, SCF and EPO, which are used together with the cytokines IL-4 and GM-CSF.
- the cultivation using the above cytokines leads to a large number of cells maturing within two to three weeks, which cells are typical of the Langerhans type in terms of morphology and marker profile. After about five weeks of culture in medium containing the seven cytokines mentioned, the cells assume the phenotype of mature dendritic cells. Typical of this stage of maturation is a loss of Birbeck granules, a decrease in CD la expression and an increasing expression of the surface markers CD 4, CD 25 and CD 80.
- the progenitor cells are first expanded using the cytokines IL-1ß, IL-3, IL-6, SCF and EPO for a period of one to two weeks. After this time, the proliferation is largely complete and the cells are transferred to a medium that contains only the cytokines IL-4 and GM-CSF. In this way, the cells can be stopped on their way of differentiation from the Langerhans 'cells to the dendritic cells at the level of the Langerhans' cells and thus all cells can be brought into an approximately equal state of differentiation. At this stage, the cells are particularly well suited to take up and process antigen.
- the dendritic cells can be enriched or purified using appropriate separation processes.
- a separation process could for example, consist of reacting the cells with monoclonal antibodies directed against the CD la surface antigen. These cell-antibody complexes can then also be separated using immunoaffinity columns or FACS (fluorescence-activated cell sorters).
- the concentration of the growth factors or cytokines used is within the concentration usually used, which has the highest efficiency in ex vivo cultures.
- IL-1 can be used in a concentration in the range of 10 ng / ml to 1,000 ng / ml
- IL-3 is used in a concentration of 1 U / ml up to 1,000 U / ml
- IL-4 is used in a concentration of 1 U / ml up to 1,000 U / ml used
- IL-6 is used from 10 U / ml up to 1,000 U / ml.
- EPO can be present in a concentration in the range of 0.1 U / ml to 10 U / ml.
- SCF is used between 10ng / ml up to 1,000ng / ml and IFN-y can be used in the range of 1U / ml to 1,000U / ml.
- concentrations used for GM-CSF are between 10 ng / ml and 1,000 ng / ml and for TNF- ⁇ between 10 U / ml and 1,000 U / ml.
- the preferred ranges for IL-1 are between 10 ng / ml and 150 ng / ml, for IL-3 between 50 U / ml and 150 U / ml, for IL-4 between 50 ng / ml and 200 ng / ml, for IL-6 between 50 U / ml and 150 U / ml, for EPO from 0.5 U / ml to 1.5 U / ml, for SCF from 10 ng / ml to 150 ng / ml, for GM-CSF from 50 ng / ml to 200 ng / ml, for TNF- ⁇ from 20 U / ml to 150 U / ml and for IFN- ⁇ from 50 U / ml to 150 U / ml. It is within the abilities of the average specialist to determine the best effectiveness of the growth factors or cytokines. There are internationally recognized standards for the above units.
- the peripheral blood precursor cells are obtained from cancer patients, which are mobilized by conventional chemotherapy and colony-stimulating factors to combine treatment therapy with broad antitumor activity with the simultaneous mobilization of peripheral blood progenitor cells.
- Mobilization can be obtained by treating patients with a standard dose of VP 16 (500 mg / m 2 ) ifosfamide (4 g / m 2 ) cisplatin (50 mg / m 2 ) and optionally epirubicin (50 mg / m 2 ) (VIP ( E) Therapy) followed by administration of G-CSF (available from Amgen) at a dose of 5 ⁇ g / kg / d subcutaneously for 12 to 14 days.
- VP 16 500 mg / m 2
- ifosfamide (4 g / m 2 ) cisplatin 50 mg / m 2
- optionally epirubicin 50 mg / m 2
- G-CSF available from Amgen
- GM-CSF which is commercially available, for example, under the trademark "Leukomax” from Sandoz AG, Basel.
- the cancer patients can also be treated with chemotherapy consisting of etoposide (VP 16), ifosfamide and cisplatin followed by the combined sequential administration of recombinant human interleukin-3 (rhIL-3) and recombinant human granulocyte macrophage colony-stimulating factor (rhGM-CSF ).
- rhIL-3 human interleukin-3
- rhGM-CSF recombinant human granulocyte macrophage colony-stimulating factor
- the present invention also encompasses a culture medium for dendritic cells comprising a combination of IL-1, IL-3, IL-6, EPO and SCF and optionally interferon-Y and TNF- ⁇ .
- a culture medium for dendritic cells comprising a combination of IL-1, IL-3, IL-6, EPO and SCF and optionally interferon-Y and TNF- ⁇ .
- Another culture medium according to the invention comprises a combination of SCF, GM-CSF and TNF- ⁇ .
- a particularly preferred culture medium for dendritic cells in the context of the present invention comprises a combination of IL-1, IL-3, IL-4, IL-6, SCF, EPO and GM-CSF.
- the culture media according to the invention are used for the in vitro generation of Langerhans cells or dendritic cells and include the above-mentioned combinations of growth factors and cytokines.
- the biologically active compounds are used in the concentrations given above. It is possible to provide suitable receptacles which are equipped with a culture medium for the cultivation of peripheral blood precursor cells, comprising the combination of growth factors described above. Such receptacles can be blood bags, microtiter plates or tissue culture bottles. Such ready-to-use receptacles are also the subject of the present invention.
- PBPC peripheral blood progenitor cells
- VP 16 500 mg / m 2
- ifosfamide 4 g / m 2
- cisplatin 50 mg / m 2 )
- VIP recombinant human G -CSF
- 12 patients with solid tumors and 6 patients with refractory non-Hodgkin lymphoma were included.
- PBPCs were collected 10 to 12 days after VIP chemotherapy.
- peripheral blood progenitor cells were removed by leukapheresis using a so-called "small volume chamber" (available from Baxter) on day 10-12 after VIP chemotherapy according to the procedure described by Brugger et al. in J. Clin. Oncol. 20, pp. 1452-1459 (1992) and Brugger et al., British J. of Haematology 84, pp. 402-407 (1993).
- small volume chamber available from Baxter
- MNC Mononuclear cells
- MNC Peripheral blood or bone marrow MNC cells were cultured as described in the prior art (eg Kanz et al., Blood, 68, 991 (1986)). MNC (1 x 10 5 ) were immobilized in methyl cellulose (0.9%) and supplemented in IMDM with 30% fetal calf serum (Paesel, Germany).
- Mononuclear cells were incubated with a biotinylated IgM anti-CD 34 monoclonal antibody, washed and applied to an avidin immunoaffinity column.
- Adsorbed CD 34 + cells were removed from the avidin column and resuspended in RPMI 1640 medium (Seromed, Germany) containing 3 mmol / L glutamine and 5 x 10 -5 mol / L ß-mercaptoethanol (Sigma, Germany) was added.
- RPMI 1640 medium Seromed, Germany
- Enriched CD 34 + cells were cultured in flat-bottomed 96-well microtiter plates at 0.5 to 15 x 10 3 cells / mL in RPMI 1640 medium supplemented with 10% fetal calf serum or various concentrations of autologous plasma.
- the combination of growth factors described above was added to the microtiter plates (total volume 200 ⁇ L / container) immediately after sowing the CD 34 + cells.
- Quadruple cultures of each of the 36 growth factor combinations tested were prepared.
- the following hematopoietic growth factors and cytokines were used: IL-1, IL-3, IL-6, GM-CSF, EPO, TNF- ⁇ , IFN-Y, SCF.
- Growth factors such as IL-1, GM-CSF, IFN-Y and SCF in a concentration of 100 ng / ml and in a concentration of 100 U / ml (IL-3 and IL-6).
- Erythropoietin was used in a concentration of 1 U / ml and TNF- ⁇ in a concentration of 50 U / ml.
- the cells were incubated for up to 28 days at 37 ° C in 5% CO2 without the addition of growth factors or medium. For analysis, each container was resuspended and washed in RPMI 1640 to remove residual growth factors. Cell viability was assessed by trypan blue dye exclusion and flow cytometric staining with propidium iodide.
- CD34 + blood precursor cells are, as indicated in Example 4, in a cell density of 0.5 to 3 ⁇ 10 4 / ml in RPMI 1640 medium in 25 ml cell culture bottles over a period of Max. Cultivated for 21 days.
- the following growth factors and cytokines are added to the culture medium: IL-1 ⁇ , IL-3, IL-6, SCF and erythropoietin in the concentrations mentioned under Example 4.
- TNF- ⁇ , GM-CSF and SCF are added to the medium.
- This antibody labeling is done using the indirect method.
- the cells are additionally labeled with antibodies against CD15 (granulocytes) and CD14 (monocytes).
- Isotype controls IgGl-FITC and IgG2a PE-conjugated
- the cells are washed twice and resuspended in 250 ⁇ l PBS without FCS addition for flow cytometric analysis.
- propidium iodide (PI) is added from each sample immediately before the measurement, and the PI-labeled dead cells are finally excluded accordingly before the analysis.
- 20,000 cells are analyzed from each sample. PO7DE95 / 00512
- CDla + cells in the culture with TNF, GM-CSF and SCF are about 20%, these cells additionally express HLA-DR molecules, which are also a marker for dendritic cells.
- HLA-DR molecules which are also a marker for dendritic cells.
- CDlc are expressed in approx. 17% and CD40 in approx. 45% of the cells. These molecules are also markers of dendritic cells.
- the medium which was complemented with IL-1, IL-3, IL-6, SCF and erythropoietin, gave a larger number of clonogenic progenitor cells, but the proportion of dendritic cells was significantly lower.
- CDla + cells were found in approx. 4% of all cells expanded ex vivo, CDlc-expressing cells were 3%, CD40-expressing cells approx. 2%.
- Table 1 shows that the addition of the cytokines IL-4 / GM-CSF to the SE 136 cocktail produced the highest yield of cells with the CD la + marker.
- the yield was up to 45% of the total nucleated cells. Depending on the purity of the affinity column, the yield can be increased up to 65%.
- the use of TNF- ⁇ / GM-CSF together with the Cocktail SE 136 resulted in a lower yield of CD la + cells.
- a large part of the cells had the markers CD 15 and CD 14, which indicates that these culture conditions favor differentiation into granulocytes and monocytes.
- Peripheral blood progenitor cells with the marker CD 34 + which were grown with IL-4 / GM-CSF, had a high percentage of CD la + cells, but showed no expansion of this cell type.
- the example therefore shows that the optimal yield of Langerhans cells / dendritic cells is obtained by a combination of the growth factors IL-4 / GM-CSF together with the factors SCF, EPO, IL-1ß, IL-3 and IL-6 .
- SE1361 SE136 IL-4 / GM-CSF + TNF- ⁇ / GM-CSF + IL-4 / GM-CSF
- 1 SE136 is a cytokine cocktail that includes SCF, EPO, IL-1ß, IL-3 and IL-6.
- dendritic cells according to the invention as antigen-presenting cells for inducing an immune response is explained in more detail on the basis of the experiment described below for the detection of the antigen presentation of tetanus toxoid.
- antigens such as tumor antigens, can also be used in this use.
- PBMCs peripheral mononuclear cells
- PBMCs 1 x 10 7 PBMCs were cultured with 1:80 diluted tetanus toxoid in medium containing 10% human serum. After seven days, 50 U / ml IL-2 was added to the cells and these were then cultivated for a further four days. The cells pre-stimulated in this way were first frozen and thawed again two days before the start of the antigen presentation experiment. This method takes advantage of the fact that the PBMCs already contain antigen-presenting cells which can take up tetanus toxoid and present them to the T cells which are also present.
- CD 34 + cells were cultured in a medium containing only the five expansion cytokines IL-1, IL-3, IL-6, SCF and EPO.
- the cells were sorted using a FACS sorter from Becton-Dickinson, two subtypes of dendritic cells being isolated, namely CD la + / CD 14 " and CD la + / CD 14 + .
- the Langerhans cells / dendritic cells described according to b) were first irradiated in order to be able to safely rule out further growth of these cells. These cells were then mixed with the pre-stimulated peripheral mononuclear cells obtained according to a) and placed in microtiter plates. In the control batches, the cells were cultured without adding tetanus toxoid, otherwise tetanus toxoid was added at a dilution of 1:80.
- the batches were cultured for two days, then - ⁇ H-thymidine was added and incubated for a further 18 hours. The cells were then harvested, washed and the counts per minute (CPM) determined. Since 3 H-thymidine is built into the cells during growth, the counts per minute are a measure of the T cell proliferation and thus a measure of the antigen presentation ability of the cells used.
- CPM counts per minute
- PBMCs alone show no proliferation
- antigen-presenting cells all the populations used alone do not show any proliferation (radiation)
- PBMCs + antigen-presenting cells show no proliferation
- PBMCs + antigen-presenting cells + tetanus toxoid show a strong proliferation, depending on the cell type used.
- the sorted LC / DC populations (CD la + / CD 14 ⁇ and CD la + / CD 14 + ) induce the greatest proliferation.
- the unsorted LC / DC population induces slightly less. This is due to the fact that this cell population also contains other cells that are not antigen-presenting.
- the KC population ie the cells containing only the expansion cytokines IL-1ß, IL-3, IL-6, SCF and EPO, only induced weaker proliferation.
- the present experiment shows that the Langerhans cells / dendritic cells, which were generated in vitro using the particularly preferred cytokine cocktail, can ingest and present antigen in an excellent manner and can induce very strong T cell responses. This property is less pronounced when IL-4 and GM-CSF are not present.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU23024/95A AU688897B2 (en) | 1994-04-14 | 1995-04-11 | Process for producing dendritic cells, cells thus produced and container for carrying out this process |
US08/727,495 US5866115A (en) | 1994-04-14 | 1995-04-11 | Process for preparing dendritic cells, cells thus produced and containers for carrying out this process |
EP95916557A EP0755439A1 (de) | 1994-04-14 | 1995-04-11 | Verfahren zur herstellung von dendritischen zellen, so erhaltene zellen und behälter zur durchführung dieses verfahrens |
JP7526628A JPH09511903A (ja) | 1994-04-14 | 1995-04-11 | 樹状突起細胞を調製する方法、かくして得られる細胞および本方法を実施するための容器 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4412794A DE4412794A1 (de) | 1994-04-14 | 1994-04-14 | Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens |
DEP4412794.4 | 1994-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995028479A1 true WO1995028479A1 (de) | 1995-10-26 |
Family
ID=6515338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE1995/000512 WO1995028479A1 (de) | 1994-04-14 | 1995-04-11 | Verfahren zur herstellung von dendritischen zellen, so erhaltene zellen und behälter zur durchführung dieses verfahrens |
Country Status (7)
Country | Link |
---|---|
US (1) | US5866115A (de) |
EP (1) | EP0755439A1 (de) |
JP (1) | JPH09511903A (de) |
AU (1) | AU688897B2 (de) |
CA (1) | CA2187770A1 (de) |
DE (1) | DE4412794A1 (de) |
WO (1) | WO1995028479A1 (de) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997029182A1 (en) * | 1996-02-12 | 1997-08-14 | The Rockefeller University | Method and compositions for obtaining mature dendritic cells |
EP0805207A1 (de) * | 1996-05-02 | 1997-11-05 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronische Expressionsplasmid für Tumorabstossungen |
WO1998014561A1 (en) * | 1996-10-04 | 1998-04-09 | Becton Dickinson And Company | Identification of a cd34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues |
WO1998035039A1 (en) * | 1997-02-06 | 1998-08-13 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
US5994126A (en) * | 1992-04-01 | 1999-11-30 | The Rockefeller University | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
WO1999063050A2 (en) * | 1998-06-02 | 1999-12-09 | Dendreon Corporation | Method for preparation and in vivo administration of antigen presenting cell composition |
US6274378B1 (en) | 1997-10-27 | 2001-08-14 | The Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
US6355238B1 (en) | 1992-11-18 | 2002-03-12 | Yale University | Specific immune system modulation |
WO2003016511A1 (en) * | 2001-08-15 | 2003-02-27 | Takara Bio Inc. | Method of extended culture for antigen-specific cytotoxic t lumphocytes |
US6602709B1 (en) | 1998-02-20 | 2003-08-05 | The Rockefeller University | Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells |
US6607722B2 (en) | 1999-04-20 | 2003-08-19 | Richard Leslie Edelson | Methods for inducing the differentiation of monocytes into functional dendritic cells |
US6852313B1 (en) | 1989-10-16 | 2005-02-08 | Amgen Inc. | Method of stimulating growth of melanocyte cells by administering stem cell factor |
US7144731B2 (en) | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
EP2251418A1 (de) | 2004-10-07 | 2010-11-17 | Argos Therapeutics, Inc. | Zusammensetzungen reifer dendritischer Zellen und Verfahren zu deren Kultivierung |
EP2351599A1 (de) * | 2008-11-14 | 2011-08-03 | Dnavec Corporation | Verfahren zur herstellung dendritischer zellen |
US8728811B2 (en) | 2002-03-25 | 2014-05-20 | Takara Bio Inc. | Process for producing cytotoxic lymphocyte |
US8765469B2 (en) | 2005-08-17 | 2014-07-01 | Takara Bio Inc. | Method of producing lymphocytes |
US8927273B2 (en) | 2003-08-22 | 2015-01-06 | Takara Bio Inc. | Process for producing cytotoxic lymphocytes |
US9845456B2 (en) | 2011-09-23 | 2017-12-19 | Inje University Industry-Academic Cooperation Foundation | Composition containing complex cytokines derived from EBV-infected B cells for inducing the maturation of dendritic cells |
WO2021230704A1 (ko) | 2020-05-15 | 2021-11-18 | 서울대학교 산학협력단 | 지방조직에서 분리된 기질혈관분획의 수지상세포의 활성화 기능을 이용한 면역 반응 증진용 조성물 |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277368B1 (en) | 1996-07-25 | 2001-08-21 | The Regents Of The University Of California | Cancer immunotherapy using autologous tumor cells combined with cells expressing a membrane cytokine |
US6458585B1 (en) | 1996-08-14 | 2002-10-01 | Nexell Therapeutics Inc. | Cytokine-free culture of dendritic cells |
DE19802540C1 (de) * | 1998-01-23 | 1998-11-19 | Univ Ludwigs Albert | Verfahren zur Herstellung von dendritischen Zellen mit niedermolekularen Fragmenten der Hyaluronsäure |
JP2002509716A (ja) | 1998-03-31 | 2002-04-02 | ユニバーシティ テクノロジー コーポレイション | テロメラーゼ抗原に対する免疫応答を惹起するための方法および組成物 |
US7402307B2 (en) * | 1998-03-31 | 2008-07-22 | Geron Corporation | Method for identifying and killing cancer cells |
WO2000012122A2 (de) * | 1998-08-27 | 2000-03-09 | Universitätsklinikum Freiburg | Niedermolekulare fragmente der hyaluronsäure zur herstellung von impfstoffen |
EP1175497B1 (de) | 1999-04-14 | 2010-04-07 | Novartis Vaccines and Diagnostics, Inc. | Zusammensetzungen und verfahren zur auslösung einer immunantwort auf basis alphavirus-vektoren-systeme |
AU4691700A (en) * | 1999-05-03 | 2000-11-17 | Governors Of The University Of Alberta, The | Shiga-like toxin as an enriching and purging agent |
WO2000073432A2 (en) * | 1999-06-01 | 2000-12-07 | Cornell Research Foundation, Inc. | Activation of dendritic cells to enhance immunity |
EP1312670A4 (de) * | 2000-08-16 | 2005-11-30 | Takara Bio Inc | Methode zur extensiven kultur von antigen-spezifischen cytotoxischen t-zellen |
US20030202963A1 (en) * | 2000-10-12 | 2003-10-30 | Cornell Research Foundation, Inc. | Method of treating cancer |
CA2950109C (en) | 2000-10-27 | 2019-02-19 | John W. Hadden | Vaccine immunotherapy for immune suppressed patients |
US20070154399A1 (en) * | 2000-10-27 | 2007-07-05 | Hadden John W | Immunotherapy for immune suppressed patients |
US20070025958A1 (en) | 2000-10-27 | 2007-02-01 | Hadden John W | Vaccine immunotherapy |
WO2003012061A2 (en) * | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
CN1993460A (zh) * | 2004-07-12 | 2007-07-04 | 索林集团意大利有限公司 | 用于培养人细胞的装置和方法 |
WO2007040105A1 (ja) * | 2005-09-30 | 2007-04-12 | Takara Bio Inc. | T細胞集団の製造方法 |
DE102007006736B4 (de) | 2007-02-07 | 2012-01-12 | Dagmar Briechle | In-vitro Testkit zur tierversuchsfreien Bestimmung des sensibilisierenden Potentials einer Substanz |
AU2008329741B2 (en) | 2007-11-28 | 2013-09-12 | Irx Therapeutics, Inc. | Method of increasing immunological effect |
WO2010132867A1 (en) | 2009-05-15 | 2010-11-18 | Irx Therapeutics, Inc. | Vaccine immunotherapy |
US9333238B2 (en) | 2009-12-08 | 2016-05-10 | Irx Therapeutics, Inc. | Method of immunotherapy for treament of human papillomavirus infection |
WO2012048298A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions |
EP3068867B1 (de) | 2013-11-16 | 2018-04-18 | Terumo BCT, Inc. | Zellenexpansion in einem bioreaktor |
FR3018819A1 (fr) * | 2014-03-19 | 2015-09-25 | Univ Bourgogne | Traitement de la reponse inflammatoire et dysimmunitaire |
WO2015148704A1 (en) | 2014-03-25 | 2015-10-01 | Terumo Bct, Inc. | Passive replacement of media |
CN106687583B (zh) | 2014-06-23 | 2020-07-24 | Jw可瑞基因株式会社 | 制备树突细胞的方法和包含所述树突细胞的组合物 |
CN106715676A (zh) | 2014-09-26 | 2017-05-24 | 泰尔茂比司特公司 | 按计划供养 |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
US11965175B2 (en) | 2016-05-25 | 2024-04-23 | Terumo Bct, Inc. | Cell expansion |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
JP6842081B2 (ja) * | 2016-09-09 | 2021-03-17 | 米満 吉和 | 単核球の調製方法 |
US11624046B2 (en) | 2017-03-31 | 2023-04-11 | Terumo Bct, Inc. | Cell expansion |
WO2018184028A2 (en) | 2017-03-31 | 2018-10-04 | Terumo Bct, Inc. | Cell expansion |
JP2024511064A (ja) | 2021-03-23 | 2024-03-12 | テルモ ビーシーティー、インコーポレーテッド | 細胞捕獲及び増殖 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020186A1 (en) * | 1992-03-30 | 1993-10-14 | Schering Corporation | In vitro generation of human dendritic cells and uses thereof |
WO1993020185A1 (en) * | 1992-04-01 | 1993-10-14 | Steinman Ralph M | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
WO1993021936A1 (en) * | 1992-04-23 | 1993-11-11 | Sloan-Kettering Institute For Cancer Research | LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF |
WO1994003587A1 (en) * | 1992-07-31 | 1994-02-17 | Eaves Connie J | Primitive hematopoietic stem cell preparations |
-
1994
- 1994-04-14 DE DE4412794A patent/DE4412794A1/de not_active Ceased
-
1995
- 1995-04-11 EP EP95916557A patent/EP0755439A1/de not_active Withdrawn
- 1995-04-11 JP JP7526628A patent/JPH09511903A/ja not_active Ceased
- 1995-04-11 WO PCT/DE1995/000512 patent/WO1995028479A1/de not_active Application Discontinuation
- 1995-04-11 CA CA002187770A patent/CA2187770A1/en not_active Abandoned
- 1995-04-11 AU AU23024/95A patent/AU688897B2/en not_active Ceased
- 1995-04-11 US US08/727,495 patent/US5866115A/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020186A1 (en) * | 1992-03-30 | 1993-10-14 | Schering Corporation | In vitro generation of human dendritic cells and uses thereof |
WO1993020185A1 (en) * | 1992-04-01 | 1993-10-14 | Steinman Ralph M | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
WO1993021936A1 (en) * | 1992-04-23 | 1993-11-11 | Sloan-Kettering Institute For Cancer Research | LIGAND FOR THE c-KIT RECEPTOR AND METHODS OF USE THEREOF |
WO1994003587A1 (en) * | 1992-07-31 | 1994-02-17 | Eaves Connie J | Primitive hematopoietic stem cell preparations |
Non-Patent Citations (4)
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6967029B1 (en) | 1989-10-16 | 2005-11-22 | Amgen Inc. | Method for increasing hematopoietic progenitor cells by stem cell factor |
US6852313B1 (en) | 1989-10-16 | 2005-02-08 | Amgen Inc. | Method of stimulating growth of melanocyte cells by administering stem cell factor |
US7144731B2 (en) | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
US5994126A (en) * | 1992-04-01 | 1999-11-30 | The Rockefeller University | Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens |
US6355238B1 (en) | 1992-11-18 | 2002-03-12 | Yale University | Specific immune system modulation |
US6300090B1 (en) | 1994-07-29 | 2001-10-09 | The Rockefeller University | Methods of use of viral vectors to deliver antigen to dendritic cells |
WO1997029182A1 (en) * | 1996-02-12 | 1997-08-14 | The Rockefeller University | Method and compositions for obtaining mature dendritic cells |
US7659119B2 (en) | 1996-02-12 | 2010-02-09 | Argos Therapeutics, Inc. | Method and compositions for obtaining mature dendritic cells |
US7198948B2 (en) | 1996-02-12 | 2007-04-03 | The Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
EP0805207A1 (de) * | 1996-05-02 | 1997-11-05 | Gesellschaft für Biotechnologische Forschung mbH (GBF) | Polycistronische Expressionsplasmid für Tumorabstossungen |
US6008004A (en) * | 1996-10-04 | 1999-12-28 | Becton Dickinson & Company | Identification of a CD34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues |
US6294381B1 (en) | 1996-10-04 | 2001-09-25 | Johanna Olweus | CD123+ dendritic cells in blood and lymphoid tissues |
WO1998014561A1 (en) * | 1996-10-04 | 1998-04-09 | Becton Dickinson And Company | Identification of a cd34+ bone marrow precursor for dendritic cells in blood and lymphoid tissues |
US5968780A (en) * | 1997-02-06 | 1999-10-19 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
WO1998035039A1 (en) * | 1997-02-06 | 1998-08-13 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
US6274378B1 (en) | 1997-10-27 | 2001-08-14 | The Rockefeller University | Methods and compositions for obtaining mature dendritic cells |
US7129037B2 (en) | 1998-02-20 | 2006-10-31 | The Rockefeller University | Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells |
US6602709B1 (en) | 1998-02-20 | 2003-08-05 | The Rockefeller University | Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells |
WO1999063050A3 (en) * | 1998-06-02 | 2000-01-27 | Dendreon Corp | Method for preparation and in vivo administration of antigen presenting cell composition |
WO1999063050A2 (en) * | 1998-06-02 | 1999-12-09 | Dendreon Corporation | Method for preparation and in vivo administration of antigen presenting cell composition |
US6607722B2 (en) | 1999-04-20 | 2003-08-19 | Richard Leslie Edelson | Methods for inducing the differentiation of monocytes into functional dendritic cells |
WO2003016511A1 (en) * | 2001-08-15 | 2003-02-27 | Takara Bio Inc. | Method of extended culture for antigen-specific cytotoxic t lumphocytes |
US7910368B2 (en) | 2001-08-15 | 2011-03-22 | Takara Bio Inc. | Method of extended culture for antigen-specific cytotoxic lymphocytes |
US8975070B2 (en) | 2002-03-25 | 2015-03-10 | Takara Bio Inc. | Process for producing cytotoxic lymphocyte |
US8728811B2 (en) | 2002-03-25 | 2014-05-20 | Takara Bio Inc. | Process for producing cytotoxic lymphocyte |
US8927273B2 (en) | 2003-08-22 | 2015-01-06 | Takara Bio Inc. | Process for producing cytotoxic lymphocytes |
EP2251418A1 (de) | 2004-10-07 | 2010-11-17 | Argos Therapeutics, Inc. | Zusammensetzungen reifer dendritischer Zellen und Verfahren zu deren Kultivierung |
US8765469B2 (en) | 2005-08-17 | 2014-07-01 | Takara Bio Inc. | Method of producing lymphocytes |
US8741639B2 (en) | 2008-11-14 | 2014-06-03 | Dnavec Corporation | Method for producing dendritic cells |
EP2351599A4 (de) * | 2008-11-14 | 2013-05-08 | Dnavec Corp | Verfahren zur herstellung dendritischer zellen |
EP2351599A1 (de) * | 2008-11-14 | 2011-08-03 | Dnavec Corporation | Verfahren zur herstellung dendritischer zellen |
US9845456B2 (en) | 2011-09-23 | 2017-12-19 | Inje University Industry-Academic Cooperation Foundation | Composition containing complex cytokines derived from EBV-infected B cells for inducing the maturation of dendritic cells |
WO2021230704A1 (ko) | 2020-05-15 | 2021-11-18 | 서울대학교 산학협력단 | 지방조직에서 분리된 기질혈관분획의 수지상세포의 활성화 기능을 이용한 면역 반응 증진용 조성물 |
Also Published As
Publication number | Publication date |
---|---|
AU2302495A (en) | 1995-11-10 |
JPH09511903A (ja) | 1997-12-02 |
CA2187770A1 (en) | 1995-10-26 |
US5866115A (en) | 1999-02-02 |
DE4412794A1 (de) | 1995-12-14 |
AU688897B2 (en) | 1998-03-19 |
EP0755439A1 (de) | 1997-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0755439A1 (de) | Verfahren zur herstellung von dendritischen zellen, so erhaltene zellen und behälter zur durchführung dieses verfahrens | |
DE4240635C2 (de) | Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren | |
DE69837491T2 (de) | Menschliche mesenchymale stammzellen aus peripherem blut | |
DE69328481T2 (de) | In vitro bildung von dentritischen zellen | |
DE60026561T2 (de) | Suppressorzellen zur prävention und behandlung von immunantworten bei transplantationen | |
EP1311658B1 (de) | Verfahren zur herstellung gebrauchsfertiger, antigenbeladener oder -unbeladener, kryokonservierter, reifer dendritischer zellen | |
EP1100878B1 (de) | Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen | |
DE69232682T2 (de) | Verfahren zur selektiven vermehrung von cd34 positiven zellen | |
DE69133332T2 (de) | Menschliche hematopoietische Stammzellen | |
DE10297513C5 (de) | In vitro Herstellung von dendritischen Zellen aus CD14+ Monocyten | |
EP2324109B1 (de) | Expansion hämopoietischer vorläufer | |
DE69733694T2 (de) | Verwendung von proteinen aus der mk familie als hämatopoietischer faktor | |
DE69734989T2 (de) | Antigenpräsentierende zellen, ein verfahren zur deren herstellung und deren verwendung als zelluläre impfstoffen | |
DE9390311U1 (de) | Neue Makrophagen mit Eignung als Wirkstoffe von pharmazeutischen Zusammensetzungen | |
WO1994016715A1 (en) | Selective cell proliferation | |
JPH06508528A (ja) | インビトロ由来ヒト好中球前駆体細胞 | |
DE60117167T2 (de) | Verfahren zur herstellung von submikropartikel-suspensionen pharmazeutischer substanzen | |
DE60016567T2 (de) | Makrophagenhaltige zusammensetzung mit antiinfektiösen und hematopoietischen eigenschaften sowie deren herstellungsmethode | |
DE60309927T2 (de) | Gen 2.2 dendritische zelllinien | |
DE60130206T2 (de) | Zusammensetzungen und verfahren zur herstellung von antigen-präsentierenden zellen | |
DE69530980T2 (de) | Population von mit myeloid-und/oder lymphoid-vorläufern angereicherten zellen und verfahren zur ihrer gewinnung und verwendung | |
Law et al. | Removal of peripheral blood monocytes by phenylalanine methyl ester has no effect on the colony growth of hematopoietic progenitor cells | |
DE69016432T2 (de) | Verfahren zur herstellung menschlicher adhärenter lymphokin-aktivierter killerzellen (alak). | |
EP0910624B1 (de) | Verfahren zur herstellung und vermehrung von lymphozyten | |
DE69916302T2 (de) | Verwendung von dendritischen zellen-depletierten zusammensetzungen zur verbesserung der transplantation von allogenen hämatopoietischen zellen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995916557 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2187770 Country of ref document: CA Ref document number: 08727495 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995916557 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995916557 Country of ref document: EP |